Arcadia Biosciences (RKDA) Income from Discontinued Operations (2022 - 2024)

Arcadia Biosciences (RKDA) has reported Income from Discontinued Operations for 3 consecutive years, with -$27000.0 the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Income from Discontinued Operations rose 88.26% year-over-year to -$27000.0; the trailing twelve-month figure through Sep 2025 stood at -$27000.0 (up 99.08% YoY), and the FY2024 full-year result was -$2.7 million, down 231.43% from the prior year.
• Income from Discontinued Operations improved to -$27000.0 in Q4 2024 per RKDA's latest filing, from -$430000.0 in the prior quarter.
• Across five years, Income from Discontinued Operations topped out at -$27000.0 in Q4 2024 and bottomed at -$2.0 million in Q2 2023.
• Historically, Income from Discontinued Operations has averaged -$696000.0 across 3 years, with a median of -$509500.0 in 2022.
• The widest YoY moves for Income from Discontinued Operations: up 88.26% in 2024, down 715.47% in 2024.
• Over 3 years, Income from Discontinued Operations stood at -$1.1 million in 2022, then jumped by 79.97% to -$230000.0 in 2023, then soared by 88.26% to -$27000.0 in 2024.
• According to Business Quant data, Income from Discontinued Operations over the past three periods registered -$27000.0, -$430000.0, and -$789000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.